Stk10, serine-threonine kinase 10, is a member of the STE20/p21-activated kinase (PAK) family. It is predominantly expressed in immune organs and is involved in the activation of ERM proteins, playing essential roles in lymphocyte aggregation and adhesion [3,4,5]. It may also be related to the regulation of ribosome biogenesis and is associated with the polo-like kinase kinase family, potentially regulating Plk1 function [2,6].

In gene knockout studies, Stk10 deficiency in mice promotes tumor growth. This is due to decreased activated/effector cytotoxic T lymphocytes (CTLs) and increased vessel density in the tumor microenvironment of prostate cancer, indicating its role in host anti-tumor response [1]. In cervical cancer cells, knockout of Stk10 promotes cell adhesion, migration, and invasion, while in prostate cancer cells, Stk10 knockout promotes cell proliferation and inhibits migration [4,5]. In acquired pure red cell aplasia, STK10 mutations block erythropoiesis by impairing ribosome biogenesis [2].

In conclusion, Stk10 has diverse biological functions. Through gene knockout mouse models, its importance in tumor-related processes such as tumor growth, cell migration, and invasion has been revealed. Additionally, its role in erythropoiesis-related diseases has also been demonstrated, contributing to our understanding of the underlying mechanisms of these diseases.